Tumor-infiltrating lymphocytes and survival in melanoma

Tumor-infiltrating lymphocytes and survival in melanoma

VJOncology

3 years
692 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Martin Mihm, Jr., MD of Brigham and Women's Hospital, Boston, MA gives an overview of his talk on open questions in the histopathology of cutaneous tumors in 2016, which was part of the session on open quesions in dermatopahtology of cutaneous tumors held at the World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. Prof. Mihm discusses new studies from the last 10 years on 1300 patients of the European Organisation for Research and Treatment of Cancer. They found a difference in survival for patients who have tumor infiltrating lymphocytes at the edge of the tumor; this seems to be a site of great biologic activity and the site of the epithelialmesenchymal transformation (where the tumor goes from the size of a nodule to metastasizing). The patients who have the best survival, are those whose lymphocytes attack this area of the tumor. This was a new finding according to Prof. Mihm. He further discusses the importance of the new drugs, ipilimumab and PD-L1 inhibitor pembrolizumab, for melanoma.
Up Next Autoplay
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Category: Melanoma and Skin Cancer
2 Views
UVA Cancer Center 10 hours
Publication in Nature Communications Confirms DRD2 as Target of ONC201
Publication in Nature Communications Confirms DRD2 as Target of ONC201
Category: News
3 Views
alexvarney 15 hours
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Category: Brain Cancer
2 Views
alexvarney 16 hours
An Advocates Perspective to Increasing Funding Resources
An Advocates Perspective to Increasing Funding Resources
Category: Kidney Cancer
38 Views
kidneycancer 1 day
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
11 Views
UVA Cancer Center 1 day
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
3 Views
Cancer-News 1 day
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
13 Views
kidneycancer 2 days
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
9 Views
kidneycancer 2 days
ProVent Trial: When Will There Be Results?
ProVent Trial: When Will There Be Results?
Category: Prostate Cancer
4 Views
CURC 2 days
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
Category: Prostate Cancer
3 Views
CURC 2 days